Immune Repertoire Sequencing Market Trends

  • Report ID: 3997
  • Published Date: Sep 09, 2025
  • Report Format: PDF, PPT

Immune Repertoire Sequencing Market Growth Drivers and Challenges:

Growth Drivers

  • Increasing Number of Launches of Novel Products – Escalating number of launches of novel products and a growing number of research and development activities carried out by key market players are estimated to propel the market demand in the predicted period. In order to characterize human B cells a company named ArcherDX launched Archer Immunoverse B cell Receptor assays in 2017. As per a Cold Spring Harbour Laboratory study, Stanford University researchers used immune repertoire sequencing to recognize the disease-associated symptom in the immune system of patients suffering from an autoimmune disease named systemic sclerosis-related pulmonary disease.

  • Rising Government Funding to Improve the Healthcare Infrastructure – Governments of various regions are offering investments and funding in order to improve the healthcare infrastructure all across the globe, which further boosts the growth of this market. As immune repertoire sequencing plays a vital role in a couple of therapeutic areas.

  • High Demand for Personalized Medicines - Rising demand for personalized medicine is expected to have a positive impact on the growth of the global immune repertoire sequencing market. Moreover, promoting the role of next-generation immune repertoire sequencing for personalized immune regulation is expected to surely support the market growth. 

Challenges

  • Accuracy Differences and Partial Techniques Utilization - Distinguishing biological changes from errors and biases introduced at various stages is a challenge in immune repertoire sequencing. Conventional and new bioinformatics techniques such as high-throughput screening and Haystack heuristics fall short due to their poor scalability and sensitivity and their limitations in providing sufficient and reliable data. Moreover, inconsistencies in data acquisition and processing in different laboratories, and barriers in immune repertoire sequencing systems are some of the significant reasons that may limit the growth of the immune repertoire sequencing market. 

  • Lack of Skilled Personnel in Lower Economic Regions

  • Discrepancies in Data Collection

Base Year

2025

Forecast Period

2026-2035

CAGR

9.6%

Base Year Market Size (2025)

USD 366.11 million

Forecast Year Market Size (2035)

USD 915.62 million

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of immune repertoire sequencing is estimated at USD 397.74 million.

The global immune repertoire sequencing market size was around USD 366.11 million in 2025 and is likely to expand at a CAGR of more than 9.6%, surpassing USD 915.62 million revenue by 2035.

North America immune repertoire sequencing market will hold around 40.8% share by 2035, driven by high healthcare spending and strong demand for immunotherapy.

Key players in the market include Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, Atreca Inc.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos